![conference banner](/images/conference-banner.jpeg)
Abstract
Inflammation is an important pathogenic mechanism in chronic heart failure (HF). The perpetuation of the inflammatory response in this syndrome may result either from excessive activation of proinflammatory cascades or disturbances in the resolution of inflammation. However, although cardiovascular research has extensively investigated the proinflammatory processes involved in chronic HF pathophysiology, the mechanisms responsible for inflammation resolution in this disease remain largely disregarded. The resolving response is currently considered an active process involving specific effectors that limit the progression of inflammation and promote tissue regeneration. This article aims at reviewing the major classes of lipid mediators of inflammation resolution, their cardiovascular, metabolic and renal protective effects that might putatively delay the onset and progression of chronic HF, and their therapeutic modulation. Furthermore, it also aims to emphasize the importance of adopting therapeutic strategies that stimulate the resolution of inflammation in chronic HF.
Keywords: Heart failure, resolution of inflammation, proresolving lipid mediators, cardiovascular/metabolic and renal protection, therapeutic modulation.
Current Drug Targets
Title:Resolving Inflammation in Heart Failure: Novel Protective Lipid Mediators
Volume: 17 Issue: 10
Author(s): Marta Reina-Couto, Luís Vale, Jorge Carvalho, Paulo Bettencourt, António Albino-Teixeira and Teresa Sousa
Affiliation:
Keywords: Heart failure, resolution of inflammation, proresolving lipid mediators, cardiovascular/metabolic and renal protection, therapeutic modulation.
Abstract: Inflammation is an important pathogenic mechanism in chronic heart failure (HF). The perpetuation of the inflammatory response in this syndrome may result either from excessive activation of proinflammatory cascades or disturbances in the resolution of inflammation. However, although cardiovascular research has extensively investigated the proinflammatory processes involved in chronic HF pathophysiology, the mechanisms responsible for inflammation resolution in this disease remain largely disregarded. The resolving response is currently considered an active process involving specific effectors that limit the progression of inflammation and promote tissue regeneration. This article aims at reviewing the major classes of lipid mediators of inflammation resolution, their cardiovascular, metabolic and renal protective effects that might putatively delay the onset and progression of chronic HF, and their therapeutic modulation. Furthermore, it also aims to emphasize the importance of adopting therapeutic strategies that stimulate the resolution of inflammation in chronic HF.
Export Options
About this article
Cite this article as:
Reina-Couto Marta, Vale Luís, Carvalho Jorge, Bettencourt Paulo, Albino-Teixeira António and Sousa Teresa, Resolving Inflammation in Heart Failure: Novel Protective Lipid Mediators, Current Drug Targets 2016; 17 (10) . https://dx.doi.org/10.2174/1389450117666160101121135
DOI https://dx.doi.org/10.2174/1389450117666160101121135 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response, and/or therapy ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Phytochemicals Resveratrol and Sulforaphane as Potential Agents for Enhancing the Anti-Tumor Activities of Conventional Cancer Therapies
Current Pharmaceutical Biotechnology Editorial Focus on Cardiovascular Disease, Diabetes and Vessel Fibrosis
Recent Patents on Cardiovascular Drug Discovery Antioxidant Effects of Natural Bioactive Compounds
Current Pharmaceutical Design Vascular Endothelium and Hypovolemic Shock
Current Vascular Pharmacology Gap Junctions as Therapeutic Targets in Brain Injury Following Hypoxia- Ischemia
Recent Patents on CNS Drug Discovery (Discontinued) Matrix Metalloproteinases as Drug Targets in Acute Pulmonary Embolism
Current Drug Targets Catastrophic Antiphospholipid Syndrome: Lessons from the “CAPS Registry”
Current Rheumatology Reviews Mitochondrial Targeting for Development of Novel Drug Strategies in Brain Injury
Central Nervous System Agents in Medicinal Chemistry Phytotherapeutics against Alzheimer’s Disease: Mechanism, Molecular Targets and Challenges for Drug Development
CNS & Neurological Disorders - Drug Targets Targeting the PI3K/Akt/mTOR Axis by Apigenin for Cancer Prevention
Anti-Cancer Agents in Medicinal Chemistry The 9p21 Locus and its Potential Role in Atherosclerosis Susceptibility; Molecular Mechanisms and Clinical Implications
Current Pharmaceutical Design Recent Patents Reveal Microtubules as Persistent Promising Target for Novel Drug Development for Cancers
Recent Patents on Anti-Infective Drug Discovery Medicinal Chemistry and Therapeutic Potential of Agonists, Antagonists and Allosteric Modulators of A1 Adenosine Receptor: Current Status and Perspectives
Current Pharmaceutical Design Redefining Cardiovascular (CV) Death as a Primary Endpoint Component in Cardiovascular Outcome Trials
Current Diabetes Reviews Host Genetic Factors and Treatment of Hepatitis C
Current Molecular Pharmacology Function of Cytosolic Chaperones in Tom70-Mediated Mitochondrial Import
Protein & Peptide Letters Investigating the Mechanism of Shengmaiyin (<i>Codonopsis pilosula</i>) in the Treatment of Heart Failure Based on Network Pharmacology
Combinatorial Chemistry & High Throughput Screening Patent Selections:
Recent Patents on Inflammation & Allergy Drug Discovery Current and Future Drugs for Appetite Regulation and Obesity Treatment
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Endothelial Expression of MHC Class II Molecules in Autoimmune Disease
Current Pharmaceutical Design